A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
Proline-proline endopeptidase-1 (PPEP-1) is a secreted metalloprotease and promising drug-target from the human pathogen Clostridium difficile. Here we describe all methods necessary for the production and structure determination of this protein.
New therapies are needed to treat Clostridium difficile infections that are a major threat to human health. The C. difficile metalloprotease PPEP-1 is a target for future development of inhibitors to decrease the virulence of the pathogen. To perform biophysical and structural characterization as well as inhibitor screening, large amounts of pure and active protein will be needed. We have developed a protocol for efficient production and purification of PPEP-1 by the use of E. coli as the expression host yielding sufficient amounts and purity of protein for crystallization and structure determination. Additionally, using microseeding, highly intergrown crystals of PPEP-1 can be grown to well-ordered crystals suitable for X-ray diffraction analysis. The methods could also be used to produce other recombinant proteins and to study the structures of other proteins producing intergrown crystals.
Clostridium difficile is one of the major causes of nosocomial antibiotic-associated diarrhea infections1. This Gram-positive anaerobic bacterium is transmitted through its spore form via the fecal-oral route. In the past decade, new ''epidemic'' or ''hypervirulent'' strains (e.g. BI/NAP1/027) caused a drastic increase in new infections and fatality rates in North America and Europe2. C. difficile-associated disease (CDAD) is a life threatening colon inflammation with high fatality rates3. The symptoms range from diarrhea4 to pseudomembranous colitis5 and the often-fatal toxic megacolon6.
Treatment of CDAD is difficult as the virulent strains are multidrug-resistant and the recurrence rate is high7. At the moment therapy includes the antibiotics metronidazole, fidaxomicin or vancomycin, or in repetitively recurrent cases fecal microbiota transplantation. New therapeutic strategies are urgently needed8. Some progress is recorded as the therapeutic monoclonal antibody Bezlotoxumab, targeting C. difficile toxin B9, has recently successfully passed phase III clinical trials and was filed for approval with the FDA and EMA. Additionally, new antibiotics are being tested at the moment at different stages of clinical trials10.
To develop effective treatment new therapeutic targets must be identified. The recently discovered C. difficile protease proline-proline endopeptidase-1 (PPEP-1; CD2830/Zmp1; E.C. 3.4.24.89) is such a promising target, as the lack of PPEP-1 in a knock-out strain decreases virulence of C. difficile in vivo11. PPEP-1 is a secreted metalloprotease12,13 cleaving two C. difficile adhesins at their C-terminus13 thus releasing the adherent bacteria from the human gut epithelium. Therefore, it is involved in maintaining the balance between the sessile and motile phenotype of C. difficile. To develop selective inhibitors against PPEP-1 and to understand how it recognizes its substrates intimate knowledge of its three-dimensional structure is indispensable. We have solved the first crystal structure of PPEP-1 alone and in complex with a substrate peptide14. PPEP-1 is the first known protease that selectively cleaves peptide bonds between two proline residues15. It binds the substrate in a double-kinked manner and stabilizes it via an extended aliphatic-aromatic network of residues located in the S-loop that covers the protease active site14. This substrate-binding mode is unique to PPEP-1 and not found in human proteases to date. This makes it a promising drug target, and off-target effects of inhibitors very unlikely.
To develop and screen selective PPEP-1 inhibitors in the future a large amount of pure and monodisperse PPEP-1 protein is needed. Furthermore, to determine the mode of binding of first inhibitors, co-crystal structures with PPEP-1 will have to be determined. In our hands PPEP-1 constantly produces intergrown crystals. Thus we have developed an optimization procedure to produce single diffraction-quality crystals of PPEP-1. In this protocol we describe in detail the production, purification, crystallization and structure solution of PPEP-114. We use intracellular expression in Escherichia coli of a PPEP-1 variant lacking the secretion signal sequence, affinity chromatography and size exclusion chromatography with removal of the purification tag, followed by microseeding16 into an optimization screen and structure determination via zinc single-wavelength anomalous dispersion (zinc-SAD)17. This protocol can be adapted for production and structure determination of other proteins (e.g. metalloproteases) and in particular for proteins producing intergrown crystals. On request, plasmid DNA of the construct (pET28a-NHis-rPPEP-1) and diffraction data can be provided for educational purposes.
1. Cloning and Construct Design
Figure 1: Schematic representation of construct pET28a-NHis-rPPEP-1 and SDS-PAGE analysis of expression and all purification steps. (A) Vector map of NHis-rPPEP-1 cloned into pET28a vector using NdeI/XhoI created with PlasMapper. (B) Schematic representation of the NHis-rPPEP-1 construct (upper panel) and the final construct after thrombin-cleavage of the 6xHis-tag with the resulting additional GSHM-sequence at the N-terminus (lower panel). SDS-PAGE analysis (C) of the expression in BL21 (DE3) Star at 37 °C for 4 hr and (D) of samples from all purification steps (M: molecular weight marker). Please click here to view a larger version of this figure.
2. Expression and Purification of rPPEP-1
Figure 2: Representative size exclusion chromatography and SDS-PAGE analysis of rPPEP-1. Size exclusion chromatogram (A280; absorbance at 280 nm) of purified untagged rPPEP-1 using a (16/600) column in Tris-HCl, pH 7.5, 200 mM NaCl at 6 °C. Based on the elution volume, rPPEP-1 migrates as expected for a 22 kDa protein, suggesting that it is predominantly monomeric. Rarely a minor fronting peak appears that corresponds to a dimer. (inset) SDS-PAGE analysis of the fractions from size exclusion chromatography (M; molecular weight marker). Every second fraction is applied. The faint bands below the main rPPEP-1 band correspond to occasionally occurring minor impurities. Please click here to view a larger version of this figure.
3. Crystallization and Crystal Optimization Using Microseeding
NOTE: rPPEP-1 crystallizes from conditions that constantly produce highly intergrown crystals not suitable for X-ray diffraction analysis (Figure 3). Therefore, an optimization strategy (Figure 4) was developed to obtain high quality crystals (Figure 5).
Figure 3: Representative crystals from initial screens. Intergrown crystals from rPPEP-1 at 12 mg/ml grown in condition. (A) Crystal screen I/38 (1.4 M sodium citrate tribasic dehydrate, 0.1 M HEPES sodium pH 7.5; 200 nl:100 nl). (B) SaltRx screen/52 (2.4 M ammonium phosphate dibasic, 0.1 M Tris pH 8.5; 100 nl:200 nl) and (C) (200 nl:100 nl). (D) SaltRx screen/96 (60% v/v Tacsimate pH 7.0, 0.1 M BIS-TRIS propane pH 7.0; 200 nl:100 nl). The Scale bar = 0.2 mm. Volume ratios are always protein:reservoir. Please click here to view a larger version of this figure.
Figure 4: Optimization procedure for rPPEP-1 crystallization. Initial crystals from rPPEP-1 at 12 mg/ml of low diffraction quality and with multiple lattices (intergrown) were reproduced in a 24-condition optimization screen. Again, only intergrown crystals were observed in conditions containing 2.55 M ammonium phosphate dibasic. A seed stock was prepared from a single intergrown crystal and diluted 1:1,000 into the same condition (microseeding). A volume of 0.5 µl of the diluted seed stock was added into the remaining clear drops and single crystals grew in almost all conditions. Please click here to view a larger version of this figure.
Figure 5: Representative crystals from optimization screen. Single crystals from rPPEP-1 at 12 mg/ml seeded with 1:1,000-dilution seed stock grown in the following conditions: (A) 2.1 M ammonium phosphate dibasic, 0.1 M Tris pH 7.5; 1.5 µl:1.5 µl; (B) 2.1 M ammonium phosphate dibasic, 0.1 M Tris pH 7.5; 2 µl:1 µl; (C) 2.25 M ammonium phosphate dibasic, 0.1 M Tris pH 8; 2 µl:1 µl; (D) 2.1 M ammonium phosphate dibasic, 0.1 M Tris pH 8; 1 µl:2 µl. (E) Mounted crystal in 0.1-0.2 µm nylon loop, grown in 2.1 M ammonium phosphate dibasic, 0.1 M Tris pH 8 (2 µl:1 µl) and cryo-protected in 2.1 M ammonium phosphate dibasic, 0.1 M Tris pH 8, 20% glycerol. The Scale bar = 0.2 mm in (A-D). Volume ration are always protein:reservoir. Please click here to view a larger version of this figure.
4. Crystal Mounting and Data Collection
NOTE: To obtain the best quality of diffraction data crystals should be mounted at the peak of their quality and size. Crystals can be stored in liquid nitrogen until they are subjected to X-ray diffraction analysis at 100 K. Therefore, the condition from which they originate must be adjusted to cryo-conditions. rPPEP-1 crystals can be cryo-protected by addition of either 20% glycerol or 30% sucrose (replacement of water in the condition by the cryo-protectant).
5. Structure Determination via Zinc-SAD
NOTE: In order to determine the structure of rPPEP-1 via zinc-SAD some basic crystallographic knowledge is needed as well as the software packages XDS20, Phenix21 and the program Coot22. For visualization of structures the program PyMOL23 or Chimera24 is needed. Data collected at the wavelength corresponding to the peak at the absorption edge of the element zinc can be used for single-wavelength anomalous dispersion (SAD)25 to obtain phase information that can be extended for all protein atoms.
Figure 6: Experimental electron density map and model of rPPEP-1 after the Phenix Autosol run. Electron density in blue at a contour level of 1.0 σ displayed in the program Coot. In this initial map the electron density is nicely resolved and the model build into the electron density. The zoom in shows the residues His142 and Glu189, as well as a water molecule. Please click here to view a larger version of this figure.
6. Structure Determination to High Resolution via Molecular Replacement
NOTE: In order to obtain high-resolution structural information about rPPEP-1 a native dataset is collected. Then a molecular replacement procedure using the software Phaser26,27 (within the Phenix software package) is employed using the structure determined via zinc-SAD as a model. This procedure can be also used later when solving structures of rPPEP-1 complexed with small molecules.
rPPEP-1 is overexpressed in several E. coli strains, with the highest yield in E. coli BL21 (DE3) Star (Figure 1C). After the first NiNTA affinity chromatography step the 6xHis-tag can be successfully cleaved off from most of the protein and in the second NiNTA step undigested protein can be completely separated from thrombin-digested protein (Figure 1D). On a S200 16/600 column untagged rPPEP-1 migrates as monomer with occasional fronti...
X-ray crystallography is still the fastest and most accurate method to determine three-dimensional near-atomic resolution structures of proteins28. However, it requires the growth of well-ordered single crystals. These are often difficult to get and the crystalline state is artificial. However, a comparison of protein structures determined by X-ray crystallography with those determined by other methods, especially NMR, shows generally a very good agreement. In the case of PPEP-1, an NMR structure published rec...
The authors have nothing to disclose.
We thank the staff at the beamline X06DA at the Swiss Light Source, Paul-Scherrer-Institute, Villigen, Switzerland for support during synchrotron data collection. We are grateful to Monika Gompert for excellent technical support. The project was supported by the University of Cologne and grant INST 216/682-1 FUGG from the German Research Council. A PhD fellowship from the International Graduate School in Development Health and Disease to C.P. is acknowledged. The research leading to these results has received funding from the European Community's Seventh Framework Program (FP7/2007-2013) under grant agreement No. 283570 (BioStruct-X).
Name | Company | Catalog Number | Comments |
Genes / Vectors / cell strains | |||
pET28a vector | Merck-Millipore | 69864 | Thrombin cleavable N-terminal His-tag |
E. coli strain BL21 (DE3) Star | ThermoFisher Scientific | C601003 | RNase H deficient |
Codon-optimized gene (for E. coli) of PPEP-1 (CD630_28300) | Geneart (Thermo Fisher Scientific) | custom | amino acids 27-220 |
Name | Company | Catalog Number | Comments |
Chemicals | |||
Yeast extract | any | ||
Tryptone | any | ||
Antifoam B | Sigma-Aldrich | A5757 | aqueous-silicone emulsion |
Agar | any | ||
Kanamycin | any | ||
IPTG | AppliChem | A1008 | |
Tris-HCl | AppliChem | A1087 | Buffer grade |
NaCl | any | Buffer grade | |
DNaseI | AppliChem | A3778 | |
Imidazole | AppliChem | A1073 | Buffer grade |
Thrombin | Sigma-Aldrich | T4648 | |
Ammonium phosphate dibasic | Sigma-Aldrich | 215996 | |
Glycerol 100% | any | purest grade | |
Sucrose | Sigma-Aldrich | 84097 | |
Liquid nitrogen | any | for storage and cryocooling of crystals | |
Name | Company | Catalog Number | Comments |
Equipment (general) | |||
Shaking incubator | any | providing temperatures of 20 °C - 37 °C | |
Glassware | any | baffled Erlenmeyer flasks (50 ml - 2.8 L) | |
Centrifuge for large culture volumes | any | centrifuge for processing volumes up to 12 L | |
Sonicator Vibra-Cell VCX500 | Sonics | SO-VCX500 | or any other sonicator / cell disruptor |
Ultracentrifuge | any | centrifuge providing speeds up to 150,000 x g | |
NiNTA Superflow resin | Qiagen | ||
Empty Glass Econo-Column | Bio-Rad | 7371007 | or any other empty glass or plastic column |
Size exclusion chromatography column HiLoad Superdex 200 16/600 | GE Healthcare | 28989335 | |
Chromatography system Äkta Purifier | GE Healthcare | 28406264 | or any other chromatography system |
Dialysis tubing Spectra/Por 3 | Spectrum Labs | 132724 | |
Dialysis tubing closures | Spectrum Labs | 132738 | |
Ultrafiltration units (concentrators) 10,000 NWCO | any | ||
UV-Vis spectrophotometer | any | ||
Name | Company | Catalog Number | Comments |
Equipment (crystallography) | |||
Low volume pipette 0.1-10 µl | any | ||
Positive displacement pipette Microman M10 | Gilson | F148501 | |
Crystallization robot | any | ||
96-well crystallization plates TTP IQ with three protein wells | TTP | 4150-05810 | or any other 96-well crystallization plate |
24-well CombiClover Junior Plate | Jena Bioscience | EB-CJR | |
Crystal Clear Sealing Tape | Hampton Research | HR3-511 | |
Siliconized Glass Cover Slides | Hampton Research | HR3-225 | |
Commercial crystallization screens: SaltRx, Index, PEG/Ion, Crystal | Hampton Research | diverse | |
Commercial crystallization screens: Wizard, PACT++, JCSG++ | Jena Bioscience | diverse | |
JBS Beads-for-Seeds | Jena Bioscience | CO-501 | |
CrystalCap SPINE HT (nylon loops) | Hampton Research | diverse | loop sizes 0.025 mm - 0.5 mm |
CrystalCap Vial | Hampton Research | HR4-904 | |
Cryogenic Foam Dewar 800 ml | Hampton Research | HR4-673 | |
Cryogenic Foam Dewar 2 L | Hampton Research | HR4-675 | |
Vial Clamp, Straight | Hampton Research | HR4-670 | |
CrystalWand Magnetic, Straight | Hampton Research | HR4-729 | |
CryoCane 6 Vial Holder | Hampton Research | HR4-711 | |
CryoSleeve | Hampton Research | HR4-708 | |
CryoCane Color Coder - White | Hampton Research | HR4-713 | |
Scalpel | any | ||
Straight microforcep | any | for manipulation of sealing tape. etc. | |
Acupuncture needle | any | e.g. from a pharmacy | |
Stereo microscope | any | for inspection of crystallization plates and crystal mounting, magnification up to 160X |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved